Introduction
Asthma is a heterogeneous chronic disease characterized by variable airflow limitation, bronchial hyperresponsiveness and airway inflammation. Severe asthma affects approximately 3–5% of patients and is associated with a high burden of symptoms, frequent exacerbations, and increased healthcare utilization. According to the Global Initiative for Asthma (GINA) 2026, severe asthma is defined as asthma that remains uncontrolled despite optimized treatment with high-dose inhaled corticosteroids-long-acting β2-agonists (ICS-LABA), after modifiable factors such as adherence, inhaler technique, comorbidities and exposures have been addressed, or that worsens when high-dose treatment is reduced [1,2].
Although asthma has traditionally been considered a disease of the central airways, increasing evidence supports the involvement of the peripheral airways as a major site of airflow limitation, particularly in severe disease. Small airways (<2 mm in diameter) contribute minimally to airway resistance in healthy lungs but become critically involved in asthma due to inflammation and structural remodelling, leading to small airway dysfunction (SAD) [3–5]. SAD has been associated with poor disease control, increased exacerbation risk, and specific clinical phenotypes, highlighting its relevance as a potential treatable trait [6,7].
SAD is increasingly recognized as a relevant feature of severe asthma and may contribute to persistent symptoms and airflow limitation despite treatment. Despite its clinical importance, the detection of SAD remains challenging. Spirometry, the gold standard for lung function assessment, mainly reflects large airway function and may underestimate peripheral airway involvement.
In this context, impulse oscillometry (IOS) allows assessment of airway resistance and reactance during tidal breathing and has shown greater sensitivity in detecting small airway abnormalities compared with conventional methods [8,9]. In recent years, the introduction of biologic therapies has revolutionized the management of severe asthma by targeting key pathways of type 2 inflammation. Currently, several monoclonal antibodies, approved and available in Italy, selectively target different components of the type 2 inflammatory cascade: omalizumab targets immunoglobulin E (IgE), while mepolizumab targets IL-5, whereas benralizumab targets IL-5 receptor α (IL-5Rα), leading to eosinophil depletion.
Dupilumab acts through IL-4 receptor α (IL-4Rα) blockade, thereby inhibiting both IL-4 and IL-13 signalling pathways. More recently, tezepelumab, targeting thymic stromal lymphopoietin (TSLP), acts upstream in the inflammatory cascade and is effective across different inflammatory phenotypes. These therapies have been shown to reduce exacerbations, improve asthma control, and decrease oral corticosteroid (OCS) use; however, evidence comparing IOS and spirometry in assessing SAD remains limited [10–13].
IOS may identify peripheral airway abnormalities not captured by conventional spirometry, including in patients with preserved spirometric values. However, available evidence remains heterogeneous, and longitudinal data in severe asthma patients treated with biologics are still limited [14–17]. The aim of this study was to compare spirometry and IOS in patients with severe asthma treated with biologics, focusing on the concordance and clinical relevance of these functional measures.
We also evaluated longitudinal changes in asthma control, OCS use, exacerbations, hospitalizations, and healthcare utilization over an 18-month follow-up.
Methods
Patients and data collection
This was a dual-centre, real-life, observational cohort study conducted at the Allergy and Clinical Immunology Unit of L. Sacco Hospital, Milan (Italy), and at the Pulmonology Unit of the Institute of Respiratory Diseases, University Aldo Moro, Bari (Italy), between December 2022 and April 2026. We enrolled 40 adult (>18 years old) patients with severe asthma according to international Global Initiative for Asthma (GINA) criteria [1], including 22 patients from the Milan centre and 18 from the Bari centre.
All patients were receiving biologic therapy as part of routine clinical care in a real-world setting. Patients with significant comorbid conditions potentially affecting airway function, such as eosinophilic granulomatosis with polyangiitis (EGPA), chronic obstructive pulmonary disease (COPD), interstitial lung disease, and other relevant chronic respiratory diseases, were excluded. Spirometric and IOS parameters were collected at baseline prior to biologic initiation (T0) and at predefined follow-up time points: 6 months (T6), 12 months (T12) and 18 months (T18), to longitudinally assess changes in lung function and small airway involvement.
For each patient, demographic data (age, sex, ethnicity, BMI, comorbidities, smoking status) and treatment variables (type of biologic therapy, initiation date, duration) were collected. Clinical status was assessed using the Asthma Control Test (ACT), where higher scores indicate better asthma control. Additional data included concomitant therapies, OCS use, severe exacerbations, emergency department visits, and asthma-related hospitalizations.
In this study, IOS measurements were performed using two different devices: Tremoflo C-100 device (Thorasys Thoracic Medical Systems Inc., Montreal, Canada) at 5–20 Hz and Master Screen (Carefusion, Hoechberg, Germany), in accordance with manufacturers’ instructions and European Respiratory Society (ERS) technical standards for oscillometry [6]. Spirometric assessments were performed using the Quark PFT system (COSMED Srl, Albano Laziale, Rome, Italy) and the Masterlab system (Carefusion, Höchberg, Germany), in accordance with the American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations [18]. The analysis included forced expiratory volume in one second (FEV1, % predicted), FEV1-to-FVC ratio (FEV1/FVC, %), and forced expiratory flow at 25–75% of vital capacity (FEF25–75, % predicted) for spirometry, as well as respiratory resistance at 5 Hz (R5, cmH2O·s/L), frequency dependence of resistance (R5–R20, cmH2O·s/L), reactance at 5 Hz (X5, cmH2O·s/L), and area of reactance (AX, cmH2O/L) for IOS.
Since IOS measurements from the two centres were obtained using different unit formats, values originally expressed in kPa·s·L−1 were converted to cmH2O·s/L, while AX values were converted from kPa/L to cmH2O/L, to standardize measurements and ensure uniformity of analyses and comparisons between devices. The cohort included patients treated with benralizumab, dupilumab, tezepelumab, and mepolizumab. Longitudinal analyses by biologic therapy were performed descriptively for benralizumab, dupilumab, and tezepelumab, and were not intended to directly compare treatment efficacy.
The single patient receiving mepolizumab was retained in all analyses of the overall cohort but was not considered a separate group for treatment-stratified longitudinal comparisons because a single observation does not allow meaningful estimation of within-group variability. Although omalizumab is an established biologic therapy for severe asthma, no omalizumab-treated patients were included in this cohort because these patients were treated earlier in our clinical practice, when oscillometry was not yet routinely available, resulting in the absence of the required pre-biologic spirometry and IOS measurements.
Statistical analysis
Qualitative variables were summarised using counts and percentages and the quantitative ones using means and standard deviations (SDs), and medians and interquartile ranges (IQRs). Scatterplots were generated to assess the relationship between quantitative variables over time. Locally weighted regression (LOESS) curves were fitted to capture potential non-linear trends, and 95% confidence bands were displayed.
Spearman correlation coefficients were computed for each time point to quantify the strength of association. Differences in quantitative variables over time were assessed using the Wilcoxon signed-rank test for paired data; pairwise comparisons between time points were performed, and p-values were adjusted for multiple testing using the Holm correction. Longitudinal changes in the outcome variables were analysed using a linear mixed-effects model with time and possible covariates as fixed effects and subject as a random intercept to account for within-subject correlation.
Statistical significance was set at p<0.05. The data were analysed using R v4.3.2 statistical software. A potential device-related effect cannot be ruled out, although the two devices have been shown to provide comparable results [19].
However, this effect is unlikely to have influenced the estimated relationships between variables (e.g., the slope of the association) or overall trends. Due to the limited sample size and the presence of missing data, no adjustment for device type was performed.
Results
Population characteristics
A total of 40 patients were included in the analysis. The cohort comprised 27 women (67.5%) and 13 men (32.5%). Most participants were of Caucasian ethnicity (90%), while 1 patient (2.5%) was African, 2 (5%) were Hispanic, and 1 (2.5%) was of Indian origin.
The mean age was 50.8 ± 16.1 years (median 54.5, IQR 37.5–64). The mean duration of asthma was 22.6 ± 14.2 years (median 21, IQR 10–28.5). Regarding anthropometric characteristics, the mean body weight was 74.4 ± 15.4 kg, and the mean height was 1.65 ± 0.09 m, resulting in a mean body mass index (BMI) of 27.2 ± 5.17 kg/m2.
Atopy, defined as sensitization to at least one aeroallergen documented by skin prick testing and/or serum specific IgE positivity, was present in 34 patients (85%). Among comorbidities, allergic rhinitis was reported in 26 patients (65%), while nasal polyposis was observed in 7 (17.5%). Non-steroidal anti-inflammatory drug (NSAID) allergy was reported in 1 patient (2.5%), atopic dermatitis in 3 (7.5%), and food allergy in 2 (5%).
With respect to smoking status, 27 patients (67.5%) were never-smokers, 2 (5%) were current smokers, and 11 (27.5%) were former smokers. Biologic therapies were distributed as follows: 9 patients (22.5%) received benralizumab, 11 (27.5%) dupilumab, 19 (47.5%) tezepelumab, and 1 patient (2.5%) mepolizumab. Regarding inhaled maintenance therapy, most patients were receiving triple therapy, including 29 treated with single-inhaler triple therapy (SITT) and 5 with multiple-inhaler triple therapy (MITT), of whom 3 were using extra-fine formulations.
The remaining 6 patients were treated with high-dose ICS/LABA therapy, including 5 receiving extra-fine formulations and 1 receiving a non–extra-fine regimen.
Correlation between IOS and spirometry parameters
A consistent negative correlation between FEF25–75 and R5–R20 was observed across all time points (r ranging from −0.52 to −0.65, p<0.01), suggesting an inverse relationship between small airway function and peripheral airway resistance, as reported in Figure 1A. A positive association between FEF25–75 and X5 was observed, although weak and less consistent across time points (r ranging from 0.17 to 0.50). The relationship appeared more variable, with greater dispersion at lower FEF25–75 values, suggesting increased heterogeneity in peripheral airway mechanics (Figure 1B).
A moderate inverse relationship between FEF25–75 and AX was observed across all time points (r ranging from −0.30 to −0.54, with p<0.05 only at T0 and T6). The relationship showed higher AX values at lower FEF25–75, suggesting greater heterogeneity in peripheral airway dysfunction at reduced lung function (Figure 1C). A consistent inverse relationship between R5 and FEV1 was observed across all time points (r ranging from −0.33 to −0.64, all p<0.01 except for T12 with p=0.12), with the strongest association at T18.
The relationship showed greater variability at lower R5 values and a tendency toward stabilization at higher levels, as described in Figure 1D.
Clinical outcomes: Exacerbations, healthcare use, OCS use and ACT
A marked reduction in exacerbation frequency was observed from baseline to 6 months (p<0.001), with median values decreasing from 3 to 0. This improvement was sustained at 12 and 18 months, with only occasional outliers, indicating a rapid and persistent reduction in exacerbation burden over time (Figure 2A). Hospitalizations were rare at baseline and completely absent during follow-up (6–18 months), indicating a marked and sustained reduction in severe disease events (p<0.05), as described in Figure 2B.
Emergency room (ER) visits markedly decreased from baseline to 6 months (p<0.05), with median values dropping from 1 to 0, and remained absent at 12 and 18 months, indicating a rapid and sustained reduction in acute healthcare utilization (Figure 2C). A significant and sustained improvement in ACT scores was observed over time (p<0.05), with median values increasing from 15.3 at baseline to 22.6 at T18, indicating a rapid achievement and maintenance of asthma control (Figure 2D). Similarly, OCS use markedly decreased over time, with 28 out of 40 patients (70.0%) receiving OCS at baseline compared to only one patient (2.5%) still requiring chronic OCS therapy at the last available follow-up, supporting a substantial reduction in OCS use following initiation of biologic therapy (p<0.001).
Longitudinal analysis of lung function parameters across biologic treatments
Differences in FEF25–75% values were observed across groups even if not significant. Temporal trends were less pronounced with a significant change only at time 18 (Figure 3A). Same results for R5–R20, as described in Figure 3B.
Exploratory longitudinal analyses suggested distinct longitudinal patterns in X5 z-scores across biologic therapy (dupilumab, benralizumab, and tezepelumab). While all groups showed similar distributions at baseline (T0), X5 z-scores showed a significant change at 18 months compared with the other time points (p<0.001), as shown in Figure 3C. The divergence observed in X5 z-score values over time may reflect differences in the longitudinal patterns of peripheral airway mechanics; however, given the limited number of patients in each subgroup, these findings should be considered exploratory and interpreted with caution.
These differences are likely influenced not only by treatment-specific mechanisms, but also by the distinct phenotypic characteristics of patients receiving each biologic agent.
Conclusions
In this longitudinal real-world study, we evaluated spirometric and IOS changes in severe asthma patients treated with biologic therapies over 18 months. The main findings of the study include a significant improvement in clinical outcomes over time, together with longitudinal changes in functional respiratory parameters and a consistent relationship between IOS and spirometric measures of small airway involvement. The inverse correlation between R5–R20 and FEF25–75 across all time points supports the role of both parameters as markers of peripheral airway dysfunction [15].
Similarly, the relationship between AX and FEF25–75 suggests increasing peripheral airway impairment with worsening small airway flow limitation. These findings are consistent with previous studies showing that IOS may detect abnormalities not fully captured by conventional spirometry, particularly in severe asthma [13–17]. Biologic therapy was associated with substantial clinical improvement.
Exacerbations, hospitalizations, ER visits, and chronic OCS use markedly decreased during follow-ups, while ACT scores improved from 15.3 at baseline to 22.6 at T18, exceeding the Minimal Clinically Important Difference (MCID) of approximately 3 points described by Schatz et al. [20], thus indicating not only a statistically significant improvement but also a clinically meaningful enhancement in asthma control. OCS use decreased from 70% of patients at baseline to only one patient at the last follow-up, supporting a relevant steroid-sparing effect of biologics. In contrast, lung function changes were less pronounced and became evident mainly at long-term follow-up.
Significant differences emerged only at T18 for R5–R20, FEF25–75, and X5 z-score, suggesting a delayed functional response of the peripheral airways in longstanding severe asthma, potentially influenced by persistent structural changes such as airway remodelling. Biologics target different components of type-2 inflammation; benralizumab and mepolizumab reduce eosinophilic inflammation through IL-5 pathway inhibition, dupilumab blocks IL-4/IL-13 signalling, while tezepelumab acts upstream by inhibiting TSLP. Despite these mechanistic differences, no significant differences between biologics were observed, in line with recent evidence showing broadly comparable efficacy among biologics in T2-high severe asthma [21].
However, descriptive longitudinal trends suggested some heterogeneity across treatments. Tezepelumab-treated patients appeared to show greater variability and a tendency toward later improvement in some peripheral airway parameters, particularly X5 and FEF25–75, whereas benralizumab and dupilumab-treated patients showed a more stable IOS profile over time, consistent with previous real-world observations [22,23]. These differences may partly reflect the underlying heterogeneity of severe asthma phenotypes and the distinct immunologic pathways targeted by the different biologic agents.
Although exploratory, this finding suggests that IOS may provide complementary information for monitoring disease control during biologic therapy. Compared with spirometry, IOS requires minimal patient cooperation and allows assessment during tidal breathing, potentially improving the evaluation of peripheral airway abnormalities in severe asthma patients [24]. The main limitations of the study are the relatively small sample size and the heterogeneity of biologic treatments.
We also acknowledge the lack of complete standardization in IOS measurements, the use of two different oscillometry devices, and the absence of universally accepted cut-off values for IOS parameters, all of which may have contributed to measurement variability and may complicate interpretation of the results [25]. However, these aspects reflect the real-world nature of the study and should be considered in the interpretation of the results. Nevertheless, the real-world design and the prolonged 18-month follow-up represent important strengths of the study.
In conclusion, our findings support in a real-life setting the long-term effectiveness of biologic therapy in severe asthma over an 18-month follow-up. The impact of treatment appeared to be more pronounced on clinical outcomes than on conventional respiratory functional parameters, with marked reductions in OCS use, exacerbations, hospitalizations, and emergency healthcare utilization, together with significant improvement in ACT scores, highlighting the substantial benefit of biologic therapy on disease burden in patients with severe asthma. This finding may reflect the chronic and complex pathophysiology of severe asthma, in which persistent airway inflammation and progressive airway remodelling may limit the extent and speed of functional recovery despite substantial clinical improvement.
Structural alterations involving epithelial damage, subepithelial fibrosis, mucus gland hyperplasia and airway smooth muscle hypertrophy may contribute to partially irreversible airflow limitation and persistent small airway dysfunction, even in patients achieving good symptom control and reduced exacerbation burden during biologic therapy [26]. Overall, these findings support the role of biologic therapy in reducing the clinical burden of severe asthma and highlight the complementary value of IOS alongside spirometry in real-world practice.